Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
Burman
W J
WJ
Denver Metro Tuberculosis Clinic, Denver Public Health and the Department of Medicine, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado 80204, USA. bburman@dhha.org
Reves
R R
RR
D000995:Antitubercular Agents / Q000009:adverse effects*; D002487:Centers for Disease Control and Prevention, U.S.; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004359:Drug Therapy, Combination; D006282:Health Personnel; D006801:Humans; D011050:Policy Making; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*; D014481:United States
D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin